New Trial Results: Kiora's KIO-301 Demonstrates Meaningful Vision Improvements in Retinitis Pigmentosa


We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclinical Phase One Phase Two Phase Three
Retinal Disease Programs
KIO-301 (Intravitreal) Retinitis Pigmentosa
Stargardt Disease
KIO-104 (Intravitreal) Posterior Non-Infectious Uveitis
KIO-301 received Orphan Drug Designation from the FDA – March 2022.
KIO-104 received Orphan Drug Designation (EU) – May 2015.
Loading RSS Feed